Week of July 2, 2012: GSK Extends Deadline for Tender Offer to Acquire Human Genome Services; Sartorius Opens New Filter, Aseptic-Bag Production Facility in Puerto Rico; and More - Pharmaceutical

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of July 2, 2012: GSK Extends Deadline for Tender Offer to Acquire Human Genome Services; Sartorius Opens New Filter, Aseptic-Bag Production Facility in Puerto Rico; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

GlaxoSmithKline (GSK) has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences (HGS) for $13.00 per share in cash to 5:00 pm EST on July 20, 2012. GSK’s tender offer will expire after July 16, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on Apr. 19, 2012, after GSK made a private proposal on Apr. 11. Read More

Merck & Co. and AstraZeneca have agreed to amend their option agreement related to their partnership known as AstraZeneca LP (AZLP), which concerns Merck’s interest in the AstraZeneca gastrointestinal drugs Prilosec (omeprazole) and Nexium (esomeprazole). The updated agreement provides that AstraZeneca will not exercise its option to acquire Merck’s remaining interest in AZLP in 2012, and provides AstraZeneca a new option to acquire Merck’s partnership interest in June 2014. Read More

Sartorius has officially opened its new filter and aseptic-bag production facility for biopharmaceutical applications at its site in Puerto Rico. The company invested approximately EUR 16 million ($20.2 million) into the expansion of its production capacity in Puerto Rico. Covering an area of 5000 m2 (53,820 ft2), the new building complex provides space for two new cleanrooms for filter and bag manufacture, laboratories, and offices. By the end of the 2012, bag-manufacturing operations will be moved from the company’s present site in Concord, California, to Yauco, Puerto Rico. There, Sartorius has added about 120 new employees and thus nearly doubled its workforce at that location. The Concord site is due to close by the end of 2012. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here